Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Launches Generic Drugs Canada

Sandoz Canada Debuts Tecfidera Rival

Novartis Subsidiary Is Among First Approved Dimethyl Fumarate Generics

  • News

Executive Summary

Sandoz has announced its launch of a generic rival to Tecfidera in Canada, with the firm among the first generics to be issued a notice of compliance by Health Canada.

You may also be interested in...



Blow For EU Tecfidera Rivals As Biogen Triumphs In Legal Battle

Developers of generic dimethyl fumarate have received a setback after a CJEU ruling in Biogen’s favor gave Tecfidera EU regulatory marketing protection until at least February 2024.

Biosimilars Rise Is Cold Comfort For Biogen As Tecfidera Competition Bites

Biosimilars sales rising by 8% to almost $800m in 2020 failed to offset the impact on Biogen of generic competition to its Tecfidera brand in the US.

Floodgates Open For Tecfidera Rivals

Following Mylan’s initial launch of a generic rival to Biogen’s $3.8bn Tecfidera brand, other generics companies are now following the firm into the US dimethyl fumarate market.

Table

View full table

Related Content

Generics Bulletin

Topics

Related Companies

Tags:
Launches Generic Drugs Canada
Latest Headlines

Shortlist Revealed Ahead Of October Awards

Rani Takes Next Step As Oral Ustekinumab Biosimilar Enters The Clinic

Amneal Outlines Ambitions To Become Leading Affordable Medicines Supplier In US

Amgen: Regulatory Reform Must Not Tie The FDA’s Hands On Evaluating Biosimilarity

See All
UsernamePublicRestriction

Register

GB151304

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By